The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Lenalidomide in conjunction with proteasome inhibitors post-stem cell transplant
Thomas Martin
• 14 Sep 2019
Thomas Martin, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA discusses the use of lenalidomide as a maintenance-based therapy, and the possibility to use it in conjunction with a proteasome inhibitor such as bortezomib in myeloma patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
